Therapeutic Advances in Diabetic Nephropathy
Diabetic kidney disease (DKD) is the most common cause of end-stage kidney disease (ESKD) in the United States. Risk factor modification, such as tight control of blood glucose, management of hypertension and hyperlipidemia, and the use of renin–angiotensin–aldosterone system (RAAS) blockade have be...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-01-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/11/2/378 |
| _version_ | 1797492956139094016 |
|---|---|
| author | Hanny Sawaf George Thomas Jonathan J. Taliercio Georges Nakhoul Tushar J. Vachharajani Ali Mehdi |
| author_facet | Hanny Sawaf George Thomas Jonathan J. Taliercio Georges Nakhoul Tushar J. Vachharajani Ali Mehdi |
| author_sort | Hanny Sawaf |
| collection | DOAJ |
| description | Diabetic kidney disease (DKD) is the most common cause of end-stage kidney disease (ESKD) in the United States. Risk factor modification, such as tight control of blood glucose, management of hypertension and hyperlipidemia, and the use of renin–angiotensin–aldosterone system (RAAS) blockade have been proven to help delay the progression of DKD. In recent years, new therapeutics including sodium-glucose transport protein 2 (SGLT2) inhibitors, endothelin antagonists, glucagon like peptide-1 (GLP-1) agonists, and mineralocorticoid receptor antagonists (MRA), have provided additional treatment options for patients with DKD. This review discusses the various treatment options available to treat patients with diabetic kidney disease. |
| first_indexed | 2024-03-10T01:13:04Z |
| format | Article |
| id | doaj.art-46809a21ff864d13b4a28b0e4fc8a05e |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-10T01:13:04Z |
| publishDate | 2022-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-46809a21ff864d13b4a28b0e4fc8a05e2023-11-23T14:13:03ZengMDPI AGJournal of Clinical Medicine2077-03832022-01-0111237810.3390/jcm11020378Therapeutic Advances in Diabetic NephropathyHanny Sawaf0George Thomas1Jonathan J. Taliercio2Georges Nakhoul3Tushar J. Vachharajani4Ali Mehdi5Department of Kidney Medicine, Glickman Urological & Kidney Institute, Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, OH 44195, USADepartment of Kidney Medicine, Glickman Urological & Kidney Institute, Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, OH 44195, USADepartment of Kidney Medicine, Glickman Urological & Kidney Institute, Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, OH 44195, USADepartment of Kidney Medicine, Glickman Urological & Kidney Institute, Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, OH 44195, USADepartment of Kidney Medicine, Glickman Urological & Kidney Institute, Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, OH 44195, USADepartment of Kidney Medicine, Glickman Urological & Kidney Institute, Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, OH 44195, USADiabetic kidney disease (DKD) is the most common cause of end-stage kidney disease (ESKD) in the United States. Risk factor modification, such as tight control of blood glucose, management of hypertension and hyperlipidemia, and the use of renin–angiotensin–aldosterone system (RAAS) blockade have been proven to help delay the progression of DKD. In recent years, new therapeutics including sodium-glucose transport protein 2 (SGLT2) inhibitors, endothelin antagonists, glucagon like peptide-1 (GLP-1) agonists, and mineralocorticoid receptor antagonists (MRA), have provided additional treatment options for patients with DKD. This review discusses the various treatment options available to treat patients with diabetic kidney disease.https://www.mdpi.com/2077-0383/11/2/378diabetesnephropathydiabetic kidney diseasetherapeuticsSGLT2MRA |
| spellingShingle | Hanny Sawaf George Thomas Jonathan J. Taliercio Georges Nakhoul Tushar J. Vachharajani Ali Mehdi Therapeutic Advances in Diabetic Nephropathy Journal of Clinical Medicine diabetes nephropathy diabetic kidney disease therapeutics SGLT2 MRA |
| title | Therapeutic Advances in Diabetic Nephropathy |
| title_full | Therapeutic Advances in Diabetic Nephropathy |
| title_fullStr | Therapeutic Advances in Diabetic Nephropathy |
| title_full_unstemmed | Therapeutic Advances in Diabetic Nephropathy |
| title_short | Therapeutic Advances in Diabetic Nephropathy |
| title_sort | therapeutic advances in diabetic nephropathy |
| topic | diabetes nephropathy diabetic kidney disease therapeutics SGLT2 MRA |
| url | https://www.mdpi.com/2077-0383/11/2/378 |
| work_keys_str_mv | AT hannysawaf therapeuticadvancesindiabeticnephropathy AT georgethomas therapeuticadvancesindiabeticnephropathy AT jonathanjtaliercio therapeuticadvancesindiabeticnephropathy AT georgesnakhoul therapeuticadvancesindiabeticnephropathy AT tusharjvachharajani therapeuticadvancesindiabeticnephropathy AT alimehdi therapeuticadvancesindiabeticnephropathy |